STOCK TITAN
  1. Home
  2. News
  3. NHWK

Scorpius Holdings, Inc. - NHWK STOCK NEWS

Welcome to our dedicated page for Scorpius Holdings news (Ticker: NHWK), a resource for investors and traders seeking the latest updates and insights on Scorpius Holdings stock.

Scorpius Holdings, Inc. (Symbol: NHWK), through its subsidiary Scorpius BioManufacturing, is an integrated Contract Development and Manufacturing Organization (CDMO) committed to advancing biologic programs from the laboratory to the clinic and beyond. Based in San Antonio, Texas, Scorpius offers a broad array of services including analytical testing, process development, and manufacturing. With a focus on quality and innovation, Scorpius provides partners in the pharmaceutical and biotech industries with state-of-the-art facilities and a highly experienced team.

Recently, Scorpius announced the appointment of Joe Payne as President and COO. Payne brings over 20 years of experience in biopharma and pharmaceuticals, having held leadership roles at Tergus Pharma and Alcami Corporation. His expertise in quality and regulatory affairs will be instrumental in Scorpius's next phase of growth, emphasizing quality biomanufacturing processes.

Under the leadership of Jeff Wolf, CEO of NightHawk Biosciences, Scorpius continues to prioritize transparent collaboration and flexible manufacturing solutions to meet the needs of its clients. The company's dedication to advancing biologic innovations efficiently and safely has made it a valuable partner in the industry.

Scorpius is currently engaged in multiple projects, including two phase 2 clinical trials for its proprietary Impact™ (Immune Pan-Antigen Cytotoxic Therapy). This first-in-class, fully human immunotherapy functions as both an immune stimulator and antigen-delivery system, targeting a wide range of cancers. The ongoing trials include HS-110 for non-small cell lung cancer (NSCLC) and HS-410 for bladder cancer.

News

Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

Rhea-AI Summary
Scorpius Holdings, Inc (NYSE American: SCPX) secures a $1 million contract with an NIH-funded researcher for therapeutic antibody development. The company will optimize and manufacture the antibody for preclinical studies, with potential expansion to Phase 1 clinical manufacturing. CEO Jeff Wolf emphasizes the company's unique capabilities and commitment to academic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium

Rhea-AI Summary
Scorpius Holdings, Inc (SCPX) joins the BioMaP-Consortium, providing access to $20 billion funding and streamlined government project access. The partnership aims to enhance biomanufacturing capabilities for medical countermeasures to combat public health threats.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Scorpius Holdings, Inc. Announces Closing of Public Offering

Rhea-AI Summary
Scorpius Holdings, Inc. (NYSE American: SCPX) closes public offering of 10,000,000 shares of common stock, generating $1,500,000 in gross proceeds. The funds will be used for working capital and general corporate purposes. ThinkEquity served as the book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
News

Scorpius Holdings, Inc. Announces Pricing of Public Offering

Rhea-AI Summary
Scorpius Holdings, Inc. (NYSE American: SCPX) announced the pricing of a public offering of 10,000,000 shares of common stock at $0.15 per share, generating $1,500,000 in gross proceeds. The offering is expected to close on March 12, 2024, with net proceeds intended for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
offering
-
News

Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
Scorpius Holdings, Inc. (NYSE American: SCPX) plans to offer shares of common stock in a public offering managed by ThinkEquity for working capital and corporate purposes. The offering is made under a shelf registration statement on Form S-3 with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
offering
-
News

Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023

Rhea-AI Summary
Scorpius Holdings, Inc. reports a significant reduction in operating loss and a record backlog for the fourth quarter of 2023. The company estimates a sequential increase in revenue of over 375% compared to the previous quarter, with a strong pipeline of new opportunities for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.68%
Tags
none
News

NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today

Rhea-AI Summary
NightHawk Biosciences / Scorpius Holdings, Inc. (NHWK; SCPX) has completed a name change to better reflect its shift into a pure-play, large molecule biomanufacturing CDMO. The name and ticker symbol changes do not affect the share structure or rights of the shareholders. The CEO, Jeff Wolf, highlighted the company's evolution into a revenue-generating biomanufacturing company and expansion of CDMO services, aiming to fill the critical void in the biopharmaceutical sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
none
-
News

NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer

Rhea-AI Summary
NightHawk Biosciences (NHWK) announces the promotion of Joe Payne to President and COO of Scorpius BioManufacturing. Payne brings over 20 years of experience in biopharma and pharmaceuticals and has held leadership roles at CDMOs Tergus Pharma and Alcami Corporation. He will oversee quality, manufacturing, process sciences, and commercial operations. CEO Jeff Wolf expressed confidence in Payne's abilities, emphasizing his expertise in developing and implementing quality production processes. Payne will focus on building a robust quality operation and working with clients to bring biologic innovations to patients efficiently and safely.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note

Rhea-AI Summary
NightHawk Biosciences, a CDMO, announced the sale of non-core IP, receiving $2.25 million from a note. The note bears interest at 1% and may be convertible into shares of NightHawk's common stock at an 8% premium. The CEO stated that the funds strengthen the balance sheet and provide additional working capital. The sale of IP aligns with the strategy to focus on Scorpius BioManufacturing subsidiary. NightHawk Biosciences, through Scorpius, offers CDMO services for biologic and cell therapy programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
News

NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program

Rhea-AI Summary
NightHawk Biosciences (NHWK) announced its Scorpius BioManufacturing subsidiary has been awarded a multimillion-dollar contract to provide process development, analytical, and cGMP manufacturing services for a biotech company’s Phase 2 clinical program. The CEO expressed pride in being selected to help advance this potentially lifesaving therapy and highlighted Scorpius' adaptability, dedicated service, and commitment to meeting project timelines. The scope of work is expected to be completed in 2024, and the company is excited to see the momentum continue as demand for its biomanufacturing services rises.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
clinical trial

FAQ

What is the market cap of Scorpius Holdings (NHWK)?

The market cap of Scorpius Holdings (NHWK) is approximately 14.9M.

What does Scorpius Holdings, Inc. do?

Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, provides contract development and manufacturing services for biologic programs.

Who is the CEO of Scorpius Holdings, Inc.?

Jeff Wolf is the CEO of NightHawk Biosciences, the parent company of Scorpius BioManufacturing.

Where is Scorpius Holdings, Inc. located?

Scorpius Holdings, Inc. is headquartered in San Antonio, Texas.

What services does Scorpius BioManufacturing offer?

Scorpius BioManufacturing offers analytical testing, process development, and manufacturing services.

What is Impact™ therapy?

Impact™ is a proprietary, fully human immunotherapy that functions as an immune stimulator and antigen-delivery system, targeting various cancers.

What clinical trials is Scorpius currently conducting?

Scorpius is conducting phase 2 clinical trials for HS-110 to treat non-small cell lung cancer and HS-410 to treat bladder cancer.

Who is Joe Payne?

Joe Payne is the President and COO of Scorpius BioManufacturing, with over 20 years of experience in biopharma and pharmaceuticals.

What makes Scorpius BioManufacturing unique?

Scorpius BioManufacturing is known for its state-of-the-art facilities, experienced team, and commitment to quality and transparent collaboration.

How can I contact Scorpius Holdings, Inc. for investor relations?

You can contact David Waldman at +1 919 289 4017 or via email at investorrelations@nighthawkbio.com.

What is the stock symbol for Scorpius Holdings, Inc.?

The stock symbol for Scorpius Holdings, Inc. is NHWK.

Stock NHWK logo
Scorpius Holdings, Inc.

NYSE:NHWK

NHWK Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NHWK Stock Data

14.90M
24.16M
7.33%
8.61%
1.18%
Biotechnology
Healthcare
Link
United States
Morrisville